E!132, SECURE, CTC Clinical Trial Consultants AB
| Reference number | |
| Coordinator | CTC Clinical Trial Consultants AB |
| Funding from Vinnova | SEK 4 637 004 |
| Project duration | May 2022 - August 2025 |
| Status | Ongoing |
| Venture | Eurostars |
Important results from the project
APC148 was tested for the first time in humans in this study, where 50–760 mg were given to healthy adults. The drug was found to be safe and well tolerated, with only mild and transient side effects. The body broke down the drug in a predictable manner, and it was mainly eliminated via urine. These results provide a safe start to continue developing APC148 as a new support in the fight against infections that are difficult to treat with standard antibiotics.
Expected long term effects
The results provide valuable information for planning future studies and may ultimately promote the development of new treatments for multidrug-resistant infections.
Approach and implementation
Projektet APC148 was conducted as planned and included all planned activities to evaluate the safety, tolerability and pharmacokinetics of the drug in healthy adults. The dosage ranged from 50 to 760 mg. The study followed the schedule without disruptions, the collaboration worked well and no unexpected events affected the project. The results provide a solid foundation for the continued development of APC148 as a complement against multidrug-resistant infections.